Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Silver

Showing results (181-190 of 232) with videos related to

Pageof 24
Sort By:
Cancer|January 15, 1980
Clinical trial of VP 16--213 (NSC 141540) I.V. twice weekly in advanced neoplastic disease: a study by the Cancer and Leukemia Group BN I Nissen, T F Pajak, L A Leone, et al.
Transplantation and Cellular Therapy|September 7, 2024
Transplant Outcomes in Myelofibrosis: Impact of Donor Type (Cord Blood Grafts Supported by CD34+ selected Cells [Haplo-Cord] Versus Matched Donors)Nima Ghalehsari, Franco Castillo Tokumori, Zhengming Chen, et al.
The Lancet. Haematology|March 31, 2022
Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendationsMonia Marchetti, Alessandro Maria Vannucchi, Martin Griesshammer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1996
Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer and Leukemia Group B studyM Perloff, L Norton, A H Korzun, et al.
Leukemia|February 9, 2016
Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or bothS Koschmieder, T I Mughal, H C Hasselbalch, et al.
American Journal of Hematology|March 5, 2020
Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failureClaire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, et al.
Nouvelle Revue Francaise D'Hematologie|January 1, 1981
Resistance to therapy of acute leukemia developing in the course of polycythemia veraP B Donovan, S A Landaw, C Dresch, et al.
The Lancet. Haematology|June 13, 2017
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre studyClaire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2009
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNetMichele Baccarani, Jorge Cortes, Fabrizio Pane, et al.
Haematologica|May 5, 2022
Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemiaKathryn E Flynn, Ehab Atallah, Li Lin, et al.
Pageof 24

Showing results (181-190 of 232) with videos related to

Sort By:
Pageof 24
Cancer|January 15, 1980
Clinical trial of VP 16--213 (NSC 141540) I.V. twice weekly in advanced neoplastic disease: a study by the Cancer and Leukemia Group BN I Nissen, T F Pajak, L A Leone, et al.
Transplantation and Cellular Therapy|September 7, 2024
Transplant Outcomes in Myelofibrosis: Impact of Donor Type (Cord Blood Grafts Supported by CD34+ selected Cells [Haplo-Cord] Versus Matched Donors)Nima Ghalehsari, Franco Castillo Tokumori, Zhengming Chen, et al.
The Lancet. Haematology|March 31, 2022
Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendationsMonia Marchetti, Alessandro Maria Vannucchi, Martin Griesshammer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1996
Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer and Leukemia Group B studyM Perloff, L Norton, A H Korzun, et al.
Leukemia|February 9, 2016
Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or bothS Koschmieder, T I Mughal, H C Hasselbalch, et al.
American Journal of Hematology|March 5, 2020
Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failureClaire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, et al.
Nouvelle Revue Francaise D'Hematologie|January 1, 1981
Resistance to therapy of acute leukemia developing in the course of polycythemia veraP B Donovan, S A Landaw, C Dresch, et al.
The Lancet. Haematology|June 13, 2017
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre studyClaire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2009
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNetMichele Baccarani, Jorge Cortes, Fabrizio Pane, et al.
Haematologica|May 5, 2022
Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemiaKathryn E Flynn, Ehab Atallah, Li Lin, et al.
Pageof 24